Nicola Gianotti

Nicola Gianotti
申请预约
职业:
传染病专家
语言:
EN
IT
申请预约

个人简介

Nicola Gianotti是IRCCS圣拉斐尔科学研究医院Turro分院传染病科的传染病专家，在Antonella Castagna教授的指导下开展工作。

1986年，Gianotti医生以优异成绩从米兰大学医学院毕业。1991年，又在该校获得内科专业学位。1996年，再度获得传染病专业学位。

在临床和研究工作中，Gianotti医生专注于治疗HIV感染（抗逆转录病毒治疗）及其并发症。此外，他还积极参与所在科室的所有日常活动。

Gianotti医生也是制定意大利抗逆转录病毒治疗指南的工作组成员。

他以作者或共同作者的身份在国际期刊上发表了多篇论文，还参与了书籍章节的编写，共计100余篇文章，H指数为21。他经常参加国际行业大会和学术会议。

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约

出版物

最新出版物

Switching antiretrovirals in older patients
Lancet HIV. 2019 Oct;6(10):e640- e641. doi: 10.1016/S2352-3018(19)30229-2. PMID: 31578950.
Gianotti N, Castagna A.
扩展阅读
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, noninferiority trial (PROBE 2)
J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. doi: 10.1093/jac/dkaa018. PMID: 32129855.
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A.
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice
AIDS Rev. 2018 Apr-Jun;20(2):75-82. doi: 10.24875/AIDSRev.M18000017. PMID: 29938701.
Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A, Gianotti N, Lo Caputo S, Maggi P, Maserati R, Maggiolo F.
Enhancing care for people living with HIV: current and future monitoring approaches. Expert Rev Anti Infect Ther
2020 Oct 15:1-14. doi: 10.1080/14787210.2021.1823217. Epub ahead of print. PMID: 33054479.
Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A.
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy
Clin Microbiol Infect. 2020 Sep 23:S1198- 743X(20)30580-2. doi: 10.1016/j.cmi.2020.09.028. Epub ahead of print. PMID: 32979570.
Lai A, Franzetti M, Bergna A, Saladini F, Bruzzone B, Di Giambenedetto S, Di Biagio A, Lo Caputo S, Santoro MM, Maggiolo F, Parisi SG, Rusconi S, Gianotti N, Balotta C.
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients
Int J Antimicrob Agents. 2020 Mar;55(3):105893. doi: 10.1016/j.ijantimicag.2020.105893. Epub 2020 Jan 9. PMID: 31926287.
Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N.
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study
J Antimicrob Chemother. 2020 Jan 1;75(1):194-199. doi: 10.1093/jac/dkz424. PMID: 31605107.
Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N.
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. PMID: 31173639.
Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group.
Evidencebased renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons
New Microbiol. 2018 Oct;41(4):247-255. PMID: 30604833.
Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, Lazzarin A.
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART
J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. PMID: 30247724.
Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group.
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen
Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13. PMID: 30009958.
Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A.
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. doi:10.1097/QAI.0000000000001522. PMID: 28816721.
Gianotti N, Marchetti G, Antinori A, Saracino A, Gori A, Rizzardini G, Lichtner M, Bandera A, Mussini C, Girardi E, dʼArminio Monforte A, Cozzi-Lepri A.
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. PMID: 28763473; PMCID: PMC5538668.
Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, Lazzarin A, Castagna A.
Icona Foundation Study and mono-PI/r database Study Cohorts. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. PMID: 28192453; PMCID:PMC5305227.
Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M;

您需要预约吗？

联系我们，我们将为您妥善安排。
申请预约